EGFR and non-small cell lung carcinoma: In the context of the generally low disease burden (including cachexia) at treatment initiation for patients with EGFR-mutated NSCLC, there is a lower probability that ramucirumab clearance may be linked to the disease status in this patient population in the absence of significant change in body weight during study treatment.